Literature DB >> 10175331

Blood donor rejection rate: HemoCue hemoglobin analyzer vs. microhematocrit.

B L Russell1, S M Martin.   

Abstract

This study compared 2 different methodologies: hemoglobin by the HemoCue instrument and hematocrit by the microhematocrit method, to determine if there were any significant difference in the values that could affect donor rejection rates. Literature from the 1960s to 1990s reveals a variety of methods for hemoglobin and hematocrit determinations as well as discussions on fingerstick versus earlobe capillary samples. The HemoCue hemoglobin analyzer is a relatively new technology that tests capillary specimens. The copper sulfate method, although the method of choice for measuring prospective donor hemoglobin levels for many years, was not a part of the study. The microhematocrit method has historically been used as the method for measuring hematocrit alone or as a secondary procedure when donors failed the copper sulfate screening test.

Entities:  

Mesh:

Year:  1997        PMID: 10175331

Source DB:  PubMed          Journal:  Clin Lab Sci        ISSN: 0894-959X


  3 in total

Review 1.  Methods and analyzers for hemoglobin measurement in clinical laboratories and field settings.

Authors:  Ralph D Whitehead; Zuguo Mei; Carine Mapango; Maria Elena D Jefferds
Journal:  Ann N Y Acad Sci       Date:  2019-06-04       Impact factor: 5.691

2.  Population-based screening for anemia using first-time blood donors.

Authors:  Alan E Mast; Whitney R Steele; Bryce Johnson; David J Wright; Ritchard G Cable; Patricia Carey; Jerome L Gottschall; Joseph E Kiss; Toby L Simon; Edward L Murphy
Journal:  Am J Hematol       Date:  2012-03-28       Impact factor: 10.047

3.  Etiology of anemia of blood donor candidates deferred by hematologic screening.

Authors:  Michel Alves da Silva; Renata Andréia Volpe de Souza; Aline Meneses Carlos; Sheila Soares; Helio Moraes-Souza; Gilberto de Araujo Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.